ImmuneOnco to report Phase I results of IMM01 on ASCO 2021
On April 26, 2021, Shanghai, China, ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. announces that Phase I results of its key product IMM01 is going to be declared on the annual meeting of the American Society of Clinical Oncology (ASCO) in 2021.The latest clinical data will be presented orally at the ASCO Annual Meeting on June 4, 2021, at section BBB 08. This is the first time for IMM01 to unveil clinical data at a top international academic conference.
The reporting tittle will be Phase I clinical trial study of IMM01 (SIRP-α-FC) for relapsed refractory lymphoma.
"We are very pleased to declare that results of IMM01 Phase I have been accepted as an oral report for ASCO Annual Meeting in 2021. IMM01 is the first product of ImmuneOnco entered clinical phase. The promising safety and efficacy included in the report make it as one of important communication forms of ASCO. It fully demonstrates the great potential of the product and will draw the international attention and be well recognized. We have full confidence in IMM01 and are accelerating the clinical development and production process, and actively advancing clinical studies on IMM01 combined with different targeted drugs." the founder of ImmuneOnco, Dr. Tian Wenzhi said.
IMM01 is a novel immune checkpoint inhibitor targeting CD47. We have global intellectual property rights on this compound. At present, IMM01 has been authorized for invention patents in China, Japan and the United States. The main mechanism of IMM01 is to block tumor CD47 and trigger potent ADCP simultaneously. By activating the phagocytosis of macrophages on tumor cells, and presenting the phagocytosed tumor antigen to T cells, IMM01 can exert a powerful effect of tumor immunotherapy. IMM01 elegantly solves the challenge of drug development on CD47 target. Phase I clinical trial of IMM01 is conducted in the GCP Center of Hematology Hospital of Chinese Academy of Medical Sciences, a first-class research institution in China.
About American Society of Clinical Oncology (ASCO)
As the largest, most authoritative and academic conference on clinical oncology in the world, the annual meeting of the American Society of Clinical Oncology (ASCO) has always been one of the most closely attended annual events in the field of oncology in the world and most important international academic meeting to present cutting-edge research achievements in clinical oncology and therapic technology.
Founded in June 2015 in the Zhangjiang Hi-Tech Park of the China (Shanghai) Pilot Free Trade Zone, ImmuneOnco focuses on the development and research of anti-tumor immunotherapy products, including bi-specific antibodies, novel recombinant proteins, and TankFounded in June 2015 in the Zhangjiang Hi-Tech Park of the China (Shanghai) Pilot Free Trade Zone, ImmuneOnco focuses on development and research of anti-tumor immunotherapy products, including bispecific antibody-traps (mAb-Traps), novel recombinant proteins, and target-activated NK cell therapy.These compounds of ours aim to activate patients’ own immune system to exert anti-tumor effects, and ultimately inhibit endless growth of tumor cells and reverse malignant symptoms, so that patients can gradually return to being healthy. Currently, several new anti-tumor products of ours are in clinical development stage. ImmuneOnco is recognized by authorities as one of the ‘Top 50 Start-up Enterprises with the Most Investment Potential in Shanghai’ in 2016, the "Excellent Enterprise" in the 2017 China Innovation and Entrepreneurship Competition, and one of the winnersof the "Enterprise Excellence Award" of Shanghai Science and Technology Entrepreneurship in 2017. cellular therapy. The common feature of these products is to activate the patient's own immune system to exert anti-tumor effects, and ultimately inhibit the endless growth of tumor cells and reverse the malignant symptoms, so that the patients gradually return to healthy. So far, several new anti-tumor drugs are in clinical stage. ImmuneOnco is recognized by authorities as one of the ‘Top 50 Start-up Enterprises with the Most Investment Potential in Shanghai’ in 2016, the "Excellent Enterprise" in the 2017 China Innovation and Entrepreneurship Competition, and the "Enterprise Excellence Award" of Shanghai Science and Technology Entrepreneurship in 2017.
Copyright: This article is from the WeChat team, welcome to forward to your moment of Wechat. Other media are not authorized to reprint in any form without permission. For reprinting authorization, please reply "reprint" in the dialogue window of our WeChat public number" ImmuneOnco ".
For further cooperation, please contact
Address: Room 502, 1043 HaLei Road, Pudong New Area, Shanghai, China
Building 7, Lane 908, Ziping Road, Pudong New Area, Shanghai, China
Tel. + 86 21 5835 6573